Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Abroad (travel likely)RecruitingPHASE1
Conditions
Breast Cancer · Hyperinsulinism · HER2-negative Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale Cancer Center Smilow Cancer Hospital, New Haven, Connecticut, United States
Study leads
Maryam Lustberg, MD, MPH
Principal Investigator
Yale University